WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics
SHANGHAI, April 17, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing ...
Read more